Spots Global Cancer Trial Database for high risk myelodysplastic syndrome
Every month we try and update this database with for high risk myelodysplastic syndrome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT01636609 | Acute Myeloid L... High Risk Myelo... | Azacitidine Cytarabine Tosedostat | 60 Years - | M.D. Anderson Cancer Center | |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | NCT01823198 | Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related... | Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological... | 7 Years - 65 Years | M.D. Anderson Cancer Center | |
| Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes | NCT02131597 | High Risk Myelo... | Guadecitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS) | NCT00840931 | Leukemia | lenalidomide bystander vacci... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | NCT03047993 | Acute Myeloid L... Blasts 20-30 Pe... Blasts 20-30 Pe... Chronic Myelomo... High Risk Myelo... IPSS Risk Categ... Myelodysplastic... | Azacitidine Glutaminase Inh... | 18 Years - | M.D. Anderson Cancer Center | |
| Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04047641 | Acute Myeloid L... Blasts 20 Perce... High Risk Myelo... Recurrent Acute... Recurrent Acute... Recurrent High ... Refractory Acut... Refractory High... | Cladribine Cytarabine Idarubicin Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00801489 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... de Novo Myelody... High Risk Myelo... Inv(16) Myelodysplastic... t(16;16) t(8;21) Untreated Adult... | Cytarabine Decitabine Filgrastim-sndz Fludarabine Pho... Gemtuzumab Ozog... Idarubicin Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia | NCT00867308 | Myelodysplastic... | Lenalidomide 50... Lenalidomide 15... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT03067571 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Daratumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | NCT04262843 | Acute Lymphobla... Acute Myeloid L... High Risk Myelo... Myelodysplastic... | Cyclophosphamid... Fludarabine Fludarabine Pho... Granulocyte Col... Hematopoietic C... Intensity-Modul... Mycophenolate M... Tacrolimus | 12 Years - 60 Years | City of Hope Medical Center | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome | NCT01873703 | Myelodysplastic... | pracinostat Placebo Azacitidine | 18 Years - | Helsinn Healthcare SA | |
| Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients | NCT01003678 | Myelodysplastic... | Clofarabine | 18 Years - | Roswell Park Cancer Institute | |
| Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia | NCT03214562 | High Risk Myelo... Recurrent Acute... Refractory Acut... | Cytarabine Filgrastim Fludarabine Idarubicin Pegfilgrastim Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | NCT02196857 | Leukemia | Azacytidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | NCT04128748 | Acute Myeloid L... Blasts More Tha... High Risk Myelo... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Liposome-encaps... Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT02141477 | Leukemia | Omacetaxine Decitabine | 70 Years - | M.D. Anderson Cancer Center | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | NCT04262843 | Acute Lymphobla... Acute Myeloid L... High Risk Myelo... Myelodysplastic... | Cyclophosphamid... Fludarabine Fludarabine Pho... Granulocyte Col... Hematopoietic C... Intensity-Modul... Mycophenolate M... Tacrolimus | 12 Years - 60 Years | City of Hope Medical Center | |
| Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | NCT03672539 | Acute Myeloid L... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Acute... Refractory Acut... | Gemtuzumab Ozog... Liposome-encaps... Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes. | NCT02689622 | Myelodysplastic... | research of dis... research of com... physical perfor... | 70 Years - | University Hospital, Toulouse | |
| Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome | NCT01873703 | Myelodysplastic... | pracinostat Placebo Azacitidine | 18 Years - | Helsinn Healthcare SA | |
| Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | NCT01593670 | Myelodysplastic... | Decitabine Vorinostat Interleukin-2 Natural killer ... | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT02029950 | Acute Myeloid L... Chronic Myelomo... High Risk Myelo... Myeloproliferat... | Cytarabine Daunorubicin Hy... Etoposide Idarubicin Hydr... Laboratory Biom... Pharmacological... Pomalidomide | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | NCT01593670 | Myelodysplastic... | Decitabine Vorinostat Interleukin-2 Natural killer ... | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome | NCT03094637 | High Risk Myelo... IPSS Risk Categ... Myelodysplastic... | Azacitidine Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00801489 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... de Novo Myelody... High Risk Myelo... Inv(16) Myelodysplastic... t(16;16) t(8;21) Untreated Adult... | Cytarabine Decitabine Filgrastim-sndz Fludarabine Pho... Gemtuzumab Ozog... Idarubicin Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | NCT03047993 | Acute Myeloid L... Blasts 20-30 Pe... Blasts 20-30 Pe... Chronic Myelomo... High Risk Myelo... IPSS Risk Categ... Myelodysplastic... | Azacitidine Glutaminase Inh... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
